---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-038517"
form_type: "8-K/A"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:07:11.309905+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vanda files financials for PONVORY acquisition; product line had $553.7M loss in FY2023 on $17.8M sales

## Summary
- Purchase price $100M for U.S./Canadian rights of PONVORY (ponesimod) from Johnson & Johnson.
- FY2023 net sales $17.8M, up from $3.9M in prior year; direct expenses $571.6M.
- Non-cash impairment of $426.1M on intangible asset, reducing net book value to $36.8M.
- Direct expenses exceeded sales by $553.7M; prior year excess was $160.3M.
- Vanda also filed unaudited pro forma condensed combined financials for year ended Dec 2023.

## SEC filing metadata
- accession: 0001193125-24-038517
- form_type: 8-K/A
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000119312524038517/0001193125-24-038517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000119312524038517/d620689d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-038517
- JSON: https://secwatch.observer/filing/0001193125-24-038517.json
- Plain text: https://secwatch.observer/filing/0001193125-24-038517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.